FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults
The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.
One-Quarter of Adults with Difficult-to-Control T2D have Hypercortisolism, According to New Data
ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.
Dapagliflozin Approved for Treatment of T2D in Children: Daily Dose
Your daily dose of the clinical news you may have missed.
5 Questions on the ADA 2024 Standards of Care in Diabetes
This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.
Older US Adults Without CVD Still Using Aspirin for Primary Prevention
Nearly one-third of US adults aged 60 years and older continue to take daily aspirin despite published evidence recommending against use in the absence of CVD.
FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use
ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.
Sugar Substitute Raises Risk of Major Adverse Cardiovascular Events: Daily Dose
SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity
ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.
Global Prevalence of T1D Rising in Older Adults: Daily Dose
CGM Data May Enhance Prediction of Risk for Type 1 Diabetes in Those with Early Stage Disease
ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.
Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial
ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.
After ACS, Long-Term Lipid Management for FH Suboptimal in Women Compared to Men
Fiver years after ACS, a new study shows women are less likely to be on lipid lowering therapy and to meet LCL-C target levels than men.
USPSTF Recommends Intensive Behavioral Interventions for Children, Teens with High BMI
The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.
WHO Issues Medical Product Alert for Counterfeit Semaglutide
Three falsified batches of semaglutide (Ozempic) are in circulation, posing risks for ineffective treatment due to incorrect dosing, contamination, and use of unknown ingredients, warned WHO.
George L Bakris, MD, Expert in Hypertension and Metabolic Disease, Has Died
Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.
ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar
Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.
Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose
Chronic Hypertension in Pregnancy Increased Two-Fold Between 2008 and 2021
The doubling of the diagnosis of chronic hypertension in pregnancy was accompanied by no increase in treatment rates, according to a new study.
New Report Shows that Despite Gains, Black Americans Still Face Higher Cardiovascular Mortality
Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.
ADA Standards of Care in Diabetes 2024: A Guideline Topline
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
